269 related articles for article (PubMed ID: 31272939)
1. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
Tannir NM; Msaouel P; Ross JA; Devine CE; Chandramohan A; Gonzalez GMN; Wang X; Wang J; Corn PG; Lim ZD; Pruitt L; Karam JA; Wood CG; Zurita AJ
Eur Urol Oncol; 2020 Oct; 3(5):687-694. PubMed ID: 31272939
[TBL] [Abstract][Full Text] [Related]
2. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for metastatic renal cell carcinoma.
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
[TBL] [Abstract][Full Text] [Related]
7. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
8. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
Sternberg CN; Davis ID; Mardiak J; Szczylik C; Lee E; Wagstaff J; Barrios CH; Salman P; Gladkov OA; Kavina A; Zarbá JJ; Chen M; McCann L; Pandite L; Roychowdhury DF; Hawkins RE
J Clin Oncol; 2010 Feb; 28(6):1061-8. PubMed ID: 20100962
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
[TBL] [Abstract][Full Text] [Related]
11. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
12. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
[TBL] [Abstract][Full Text] [Related]
13. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
14. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
[TBL] [Abstract][Full Text] [Related]
17. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
19. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
[TBL] [Abstract][Full Text] [Related]
20. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
